Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

1457 - Gemcitabine plus afatinib versus gemcitabine alone in metastatic pancreatic cancer: an explorative randomized AIO phase II trial (ACCEPT)


21 Oct 2018


Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology


Cytotoxic Therapy

Tumour Site

Pancreatic Adenocarcinoma


Michael Haas


Annals of Oncology (2018) 29 (suppl_8): viii205-viii270. 10.1093/annonc/mdy282


M. Haas1, D. Waldschmidt2, M. Stahl3, A. Reinacher-Schick4, J. Freiberg-Richter5, F. Kaiser6, S. Kanzler7, N. Frickhofen8, T. Seufferlein9, T. Dechow10, R.J.C. Mahlberg11, P. Malfertheiner12, G. Illerhaus13, S. Kubicka14, S. Held15, C.B. Westphalen1, S. Kruger1, S. Boeck1, V. Heinemann1

Author affiliations

  • 1 Department Of Medicine Iii, University Hospital, LMU Munich, 81377 - Munich/DE
  • 2 Department Of Gastroenterology And Hepatology, University of Cologne, Cologne/DE
  • 3 Department Of Medical Oncology, Kliniken Essen-Mitte, Essen/DE
  • 4 Department Of Hematology, Oncology And Palliative Medicine, St. Josef-hospital, Ruhr University Bochum, Bochum/DE
  • 5 Practice, Hematology and Oncology, Dresden/DE
  • 6 Vk&k, Studien GbR, Landshut/DE
  • 7 Department Of Internal Medicine Ii, Leopoldina Krankenhaus Schweinfurt, Schweinfurt/DE
  • 8 Hematology, Medical Oncology And Palliative Care, HELIOS Dr. Horst Schmidt Kliniken Wiesbaden, 65199 - Wiesbaden/DE
  • 9 Department Of Internal Medicine I, Ulm Medical University, 89081 - Ulm/DE
  • 10 Practice, Hematology and Oncology, 88212 - Ravensburg/DE
  • 11 Innere Medizin I, Klinikum Mutterhaus der Borromäerinnen, 54290 - Trier/DE
  • 12 Clinic Of Gastroenterology, Hepatology, And Infectious Diseases, Otto von Guericke University Magdeburg, Magdeburg/DE
  • 13 Department Of Hematology And Oncology, Klinikum Stuttgart, Stuttgart/DE
  • 14 Cancer Center Reutlingen, Klinikum am Steinenberg Reutlingen, 72764 - Reutlingen/DE
  • 15 Clinassess, GmbH, 51379 - Leverkusen/DE

Abstract 1457


Pancreatic cancer (PC) remains a disease difficult to treat. Afatinib, a novel, oral irreversible ErbB family blocker has shown efficacy in non-small-cell lung cancer bearing driver mutations of the epidermal growth factor receptor. This open-label, multicenter, randomised phase II trial evaluated the efficacy and safety for gemcitabine/afatinib vs. gemcitabine in metastatic PC.


Patients with histologically proven metastatic PC were randomised in a 2:1 ratio to receive either gemcitabine (1000mg/m2 i.v. weekly for three weeks followed by one week of rest, repeated every four weeks) and afatinib (40mg orally once daily) vs. gemcitabine alone as first-line treatment for metastatic disease. Overall survival (OS) was the primary endpoint.


Between April 2013 and January 2017, 119 patients from 25 German centers were randomised (79 patients for gemcitabine/afatinib and 40 for gemcitabine), of which 115 received at least one dose of study medication and 108 were eligible for the primary analysis. Median OS was 7.3 months for gemcitabine/afatinib vs. 7.4 months for gemcitabine, HR 1.06 (95% CI 0.68-1.65), p = 0.80. Median progression free survival (PFS) was 3.9 months for gemcitabine/afatinib vs. 3.8 months for gemcitabine, HR 0.87 (95% CI 0.56-1.34), p = 0.52. The objective overall response rate (ORR) was 9.9% for gemcitabine/afatinib vs. 10.8% for gemcitabine, respectively (p > 0.99). The rate of serious adverse events (SAEs) per patient was slightly higher for gemcitabine/afatinib vs. gemcitabine (1.66 vs. 1.53). The rate of adverse events was higher for gemcitabine/afatinib vs. gemcitabine, e.g. for main adverse events known for afatinib like diarrhoea (71% vs. 13%), epistaxis (33% vs. 0%) and skin rash (70% vs. 5%). However, the share of grade ≥3 in these events was low (16% for diarrhoea, 0% for epistaxis, 5% for skin rash; no grades 4 or 5).


The addition of afatinib to gemcitabine did not improve treatment efficacy. The combination had an acceptable safety profile with the main side effects for afatinib ranging within the known scope.

Clinical trial identification

EudraCT: 2011-004063-77; NCT01728818.

Legal entity responsible for the study

LMU Munich.


Boehringer Ingelheim.

Editorial Acknowledgement


M. Haas: Research funding and travel grant: Boehringer Ingelheim. D. Waldschmidt: Consulting or advisory role: Bayer, Health Pharma BMS, Celgene Novartis, Roche, Pharma AG, Shire Baxalta, Sirtex; Honoraria: Bayer, Health Pharma BMS, Celgene, Novartis, Shire Baxalta, Sirtex; Research funding: Roche, Pharma AG, Shire Baxalta. A. Reinacher-Schick: Honoria: Amgen, Roche, Pfizer, Sanofi-Aventis, Merck, Shire, Celgene, Lilly, BMS, Advisory board member: Amgen, Roche, Pfizer, Sanofi-Aventis, Merck, Celgene, Lilly, BMS Studies sponsored by: Roche, Sanofi-Aventis, Celgene, Ipsen. T. Seufferlein: Research support: Celgene Shire Sanofi-Genzyme; Advisory board membership: Roche Celgene, Bayer, Shire. C.B. Westphalen: Consulting or advisory role: Celgene, Roche, Pharma, AG Shire, RedHill; Honoraria: IPSEN; Research funding: Roche Pharma AG. V. Heinemann: Honoraria: Amgen, Baxalta, Celgene, Merck, Roche, Sanofi, Sirtex, Medical; Consulting or advisory role: Amgen, Baxalta, Boehringer, Ingelheim, Celgene, Merck, Roche, Sanofi, Sirtex Medical; Research funding (institution): Amgen, Bayer, Boehringer Ingelheim, Celgene, IntegraGen, Merck, Roche, Sanofi, Sirtex Medical, Taiho Pharmaceutical; Travel accommodations expenses: Amgen Baxalta, Merck, Roche, Sirtex Medical. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.